Germany is the bigger Diabetic Retinopathy Drugs market: $395 Mn against $281 Mn in 2023, about 1.4 times as large.
Germany grows faster: 4.2% a year, against 4%.
Clinical research: 14 active trials in the UK, 11 in Germany.
| Measure |  UK |  Germany |
|---|---|---|
| Market size, 2023 | $281 Mn | $395 Mn |
| Market size, 2033 projected | $416 Mn | $597 Mn |
| Growth a year (CAGR) | 4% | 4.2% |
| Money added, 2023–2033 | $135 Mn | $201 Mn |
| Share of the world market | 2.6% | 3.7% |
| Size rank of 24 countries | #7 | #5 |
| Market per person, 2023 | $4.04 | $4.73 |
| Active clinical trials | 14 | 11 |
| Diabetes (adults) % of adults (WHO) | 8.8 2022 | 6.6 2022 |
| Full report | UK report | Germany report |
Year by year, 2023 to 2033
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
UK Germany · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Diabetic Retinopathy Drugs, UK or Germany?
Germany is the bigger Diabetic Retinopathy Drugs market: $395 Mn against $281 Mn in 2023, about 1.4 times as large.
Which grows faster in Diabetic Retinopathy Drugs, UK or Germany?
Germany grows faster: 4.2% a year, against 4%.
More Diabetic Retinopathy Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Health figures: WHO. Population: World Bank.